560 related articles for article (PubMed ID: 14667953)
1. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
[TBL] [Abstract][Full Text] [Related]
4. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
Weinberg JM; Saini R; Tutrone WD
J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
[TBL] [Abstract][Full Text] [Related]
6. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
Saini R; Tutrone WD; Weinberg JM
Curr Pharm Des; 2005; 11(2):273-80. PubMed ID: 15638763
[TBL] [Abstract][Full Text] [Related]
7. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
9. Advancements in the treatment of psoriasis: role of biologic agents.
Rich SJ; Bello-Quintero CE
J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
[TBL] [Abstract][Full Text] [Related]
10. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept.
Tutrone WD; Saini R; Weinberg JM
IDrugs; 2004 Jan; 7(1):45-9. PubMed ID: 14730466
[TBL] [Abstract][Full Text] [Related]
11. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
12. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
13. Practical understanding of mean percent psoriasis area and severity index reduction for biologics.
English PL; Vender R
J Cutan Med Surg; 2008; 12(6):282-7. PubMed ID: 19317950
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
15. Understanding the new clinical landscape for psoriasis: a comparative review of biologics.
Sauder DN; Mamelak AJ
J Cutan Med Surg; 2004; 8(4):205-12. PubMed ID: 16091996
[TBL] [Abstract][Full Text] [Related]
16. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
[TBL] [Abstract][Full Text] [Related]
17. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment.
Anstey AV; Kragballe K
Int J Dermatol; 2006 Aug; 45(8):970-5. PubMed ID: 16911387
[TBL] [Abstract][Full Text] [Related]
18. Biologicals in the treatment of psoriasis.
Boker A; Kimball AB; Rolz-Cruz G
Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
[TBL] [Abstract][Full Text] [Related]
19. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
